At J.P. Morgan conference, Illumina shares new sequencing-by-synthesis chemistry and gears up for its long-read Infinity launch later this year, plus numerous collaborations and numbers that beat Wall Street expectations.
Illumina has unveiled new technologies intended to enhance future next-generation sequencing solutions, along with numerous collaborations and updates, including a preview of results that CEO Francis deSouza said reflected a “very strong” fourth quarter and “exceptional” 2021. [Illumina]
Illumina CEO Francis deSouza disclosed that his company has developed a new sequencing-by-synthesis (SBS) chemistry—codenamed “Chemistry X” pending a permanent name. He said Chemistry X will deliver 2x faster cycle times, as well as 2x longer reads, and 3x greater accuracy than the company’s current SBS chemistry. Additional details of Chemistry X are expected to emerge this fall, when Illumina holds its annual customer/investor day . . .
